Our laboratory focuses on unraveling the neuroinflammatory processes triggered by acute excitotoxic events, such as status epilepticus and cerebral ischemia. Recently, we have expanded our research to investigate neuron–glia interactions in malignant gliomas—aggressive brain tumors that are a leading cause of epilepsy, particularly in older adults. We aim to elucidate the molecular and cellular mechanisms that drive transformation of a normal brain into one capable of generating seizures during epileptogenesis. In addition, we are committed to developing novel pharmacotherapies for these inflammation-related conditions through close collaboration with medicinal chemistry teams.
To support these efforts, we utilize a broad range of advanced technologies and experimental approaches, including high-throughput screening, lead optimization, in vivo PK, chemical genetics, TR-FRET, RNAi, CRISPR, multi-omics, unbiased stereology, time-locked video EEG, and diverse behavioral assays. Together, these efforts allow us to bridge fundamental neuroscience with translational innovation—advancing scientific understanding while paving the way toward new treatments for brain disorders.